Advertisement
Screener

BioNexus Gene Lab Corp. (BGLC) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

BioNexus Gene Lab Corp. Stock-Based Compensation

BioNexus Gene Lab Corp. (BGLC) reported Stock-Based Compensation of $794.77 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-14.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2026-04-14

  • BioNexus Gene Lab Corp. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $794.77K.
  • BioNexus Gene Lab Corp. share-based payment arrangement, noncash expense for the quarter ending 2024-12-31 was $0.00.
  • BioNexus Gene Lab Corp. share-based payment arrangement, noncash expense for fiscal 2025 was $794.77K, a 463.67% increase from fiscal 2024.
  • BioNexus Gene Lab Corp. share-based payment arrangement, noncash expense for fiscal 2024 was $141.00K.
Period endShare-based Payment Arrangement, Noncash Expense 3 monthShare-based Payment Arrangement, Noncash Expense 9 monthShare-based Payment Arrangement, Noncash Expense 12 month
2025-12-31$794.77K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14
$794.77K
10-K · filed 2026-04-14
2025-09-30$0.00
10-Q · filed 2025-11-14
2024-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14
$141.00K
10-K · filed 2026-04-14
2024-09-30$141.00K
10-Q · filed 2025-11-14
2023-09-30$601.74K
10-Q · filed 2024-11-15
2022-09-30$0.00
10-Q/A · filed 2024-03-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aclarion, Inc. (ACON)United States$0.008B
Advanced Biomed Inc. (ADVB)$0.009B
AMERICAN SHARED HOSPITAL SERVICES (AMS)United States$0.010B-5.64
SERA PROGNOSTICS, INC. (SERA)United States$0.062B-5.75
Freenome, Inc. (FRNM)United States$0.143B
EXAGEN INC. (XGN)United States$0.212B-5.95
BIODESIX INC (BDSX)United States$0.312B
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45